期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 34, 期 7, 页码 393-400出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2013.04.007
关键词
protein-protein interaction; cancer genomics; signaling network; high-throughput screening; small-molecule modulator; tumorigenesis
资金
- US National Institutes of Health [P01CA116676, U01 CA168449]
The emergence and convergence of cancer genomics, targeted therapies, and network oncology have significantly expanded the landscape of protein protein interaction (PPI) networks in cancer for therapeutic discovery. Extensive biological and clinical investigations have led to the identification of protein interaction hubs and nodes that are critical for the acquisition and maintenance of characteristics of cancer essential for cell transformation. Such cancer-enabling PPIs have become promising therapeutic targets. With technological advances in PPI modulator discovery and validation of PPI-targeting agents in clinical settings, targeting of PPI interfaces as an anticancer strategy has become a reality. Future research directed at genomics-based PPI target discovery, PPI interface characterization, PPI-focused chemical library design, and patient-genomic subpopulation-driven clinical studies is expected to accelerate the development of the next generation of PPI-based anticancer agents for personalized precision medicine. Here we briefly review prominent PPIs that mediate cancer-acquired properties, highlight recognized challenges and promising clinical results in targeting PPIs, and outline emerging opportunities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据